Last reviewed 2026-05-27 · How we verify

Tiazolidin (TIMONACIC)

Phase 2 active Small molecule ✓ Verified May 2026

Tiazolidin (generic name: TIMONACIC) is a timonacic drug. It is currently in Phase 2 development.

Timonacic is thought to work by binding to a specific target, although the exact target and mechanism are not yet fully understood.

Tiazolidin is a small molecule with the synonyms HEPACOM, NORGAMEN, NSC-25855, TIMONACIC, and TIMONACICO.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TIMONACIC
Drug class	timonacic
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and each lock has a unique key. Timonacic is like a key that fits into one of these locks, but we don't yet know which lock it is or what it does when it's inside. This binding process is thought to affect the way cells work, but the details are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tiazolidin CI brief — competitive landscape report
Tiazolidin updates RSS · CI watch RSS

Frequently asked questions about Tiazolidin

What is Tiazolidin?

Tiazolidin (TIMONACIC) is a timonacic drug.

How does Tiazolidin work?

Timonacic is thought to work by binding to a specific target, although the exact target and mechanism are not yet fully understood.

What is the generic name of Tiazolidin?

TIMONACIC is the generic (nonproprietary) name of Tiazolidin.

What drug class is Tiazolidin in?

Tiazolidin belongs to the timonacic class. See all timonacic drugs at /class/timonacic.

What development phase is Tiazolidin in?

Tiazolidin is in Phase 2.

Drug class: All timonacic drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing